We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Quick reference guide to apixaban.
- Authors
Hurst, Katherine Victoria; O'Callaghan, John Matthew; Handa, Ashok
- Abstract
Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and consequent prescription of specified doses) and no requirement for routine monitoring. Apixaban is a selective factor Xa inhibitor, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation and in the prevention and treatment of acute VTE. Like many of the DOACs, it has a fast onset of action and works to deliver predictable coagulation results. Multiple randomized controlled trials including ARISTOTLE and AMPLIFY have shown apixaban to be noninferior to vitamin K antagonists in the prevention of stroke and VTE, with a good safety profile. This article aims to review the use of apixaban for the prevention and treatment of thromboembolic disease, highlighting the key study results that have led to its current licensing and use.
- Subjects
ANTICOAGULANTS; APIXABAN; STROKE; THROMBOEMBOLISM; ATRIAL fibrillation; VITAMIN K; THROMBOEMBOLISM prevention; STROKE prevention; BLOOD coagulation; HEMORRHAGE; HETEROCYCLIC compounds; ORAL drug administration; PYRIDINE; VEINS; TREATMENT effectiveness; BLOOD
- Publication
Vascular Health & Risk Management, 2017, Vol 13, p263
- ISSN
1176-6344
- Publication type
journal article
- DOI
10.2147/VHRM.S121944